Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs

Withdrawn

• Conditions: Carcinoma, Non-Small-Cell Lung; Carcinoma Bladder; Carcinoma of the Oral Cavity; Stage III Breast Cancer; Carcinoma, Renal Cell; Carcinoma, Small Cell Lung; Carcinoma of the Head and Neck; Carcinoma of the Anus; Carcinoma of the Larynx; Carcinoma of the Vulva

• Registration Number: NCT04985357
• Lead Sponsor: Travera Inc

Brief Summary

The primary objective of this study, sponsored by Travera in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using isolated tumor cells from varying cancers and biopsy formats.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2021-07-15
• Study First Submitted QC: 2021-07-28
• Study First Posted: 2021-08-02
• Status Verified: 2024-11
• Study Start: 2024-11
• Last Update Submitted: 2024-11-21
• Last Update Posted: 2024-11-25
• Primary Completion: 2028-05
• Study Completion: 2030-05

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: 630

Inclusion Criteria

• Sample collection or biopsy of tumor is clinically indicated as part of SOC
• Prior to preceding onto therapy for treatment

Exclusion Criteria

• Unable to obtain sufficient sample

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Best overall response (BOR)	up to 24 months	The best overall response to therapy over 24 months will be captured for correlation with test outcomes.